Longshen Rongfa: Net profit in 2025 is expected to increase by 79.56% year-on-year, with a proposed dividend of 0.2 yuan per 10 shares.

People Finance News, April 2. Longshenrongfa (300534) disclosed its annual report on April 2. In 2025, it achieved operating revenue of 887 million yuan, a year-on-year decrease of 14.92%; net profit attributable to shareholders was 43.9508 million yuan, a year-on-year increase of 79.56%; and basic earnings per share were 0.1449 yuan. The company plans to distribute a cash dividend of 0.2 yuan for every 10 shares (including tax). During the reporting period, the main reasons for the changes in performance are: First, it adhered to strengthening Longyao’s key product categories, increased efforts to boost market sales of its flagship products, expanded and developed blank markets through multiple channels, and actively carried out cooperation with leading pharmacy chains to enhance OTC channel sales. For the flagship products Yuanhu Zhitong Dropping Pills and Xuanfei Zhisu Mixture, the company newly developed Grade A hospitals of 233 and 357 respectively throughout the year. In total, it covered 2,983 and 2,324 Grade A hospitals, respectively, increasing by 6.27% and 7.57% compared with the previous year. Second, it tapped the growth potential of general medicines, cultivated new growth drivers, and developed new momentum. Compound Danshen Tablets were selected for the sixth batch of the centralized procurement directory for drugs in Gansu Province, as well as the centralized procurement directories in Guangdong and the Beijing-Tianjin-Hebei region. In addition, for the health food Huangqi Danggui Capsules, it obtained approval from the Macao Special Administrative Region government’s Drug Administration for a non-drug recognition.